secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001213900-25-019747
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal Therapeutics signs collaboration with Abbott to support Phase 3 LVAD trial of tecarfarin
--------------------------------------------------------------------------------

- Abbott will share LVAD data from MOMENTUM 3 and ARIES HM3 trials for TECH-LVAD trial design.
- Abbott to assist with biostatistics, site selection, patient enrollment, and medical science liaison.
- Cadrenal is regulatory sponsor; tecarfarin-related IP owned by Cadrenal, device-related IP by Abbott.
- Phase 3 TECH-LVAD trial compares tecarfarin vs warfarin in HeartMate 3 LVAD patients with open-label extension.
- No upfront or milestone payments disclosed; Cadrenal still pursuing additional funding partnerships for the study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390025019747/0001213900-25-019747-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390025019747/ea0231833-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-019747

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer